Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries

摘要

ObjectivesDifferences in marketed prices of antiretrovirals raises questions about the fairness of pricing medicines of significant public health importance such as dolutegravir (DTG). In view of the reduced prices of generically available efavirenz (EFV), there is a need to determine if previous conclusions on DTG's cost-effectiveness need to be re-assessed